Pacira Biosciences, Inc. (PCRX)
36.48
0.00 (0.00%)
USD |
NASDAQ |
Nov 17, 16:00
Pacira Biosciences Net Income (Quarterly) : 28.52M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 28.52M |
| June 30, 2026 | 4.653M |
| March 31, 2026 | 2.916M |
| December 31, 2025 | 1.637M |
| September 30, 2025 | 5.432M |
| June 30, 2025 | -4.847M |
| March 31, 2025 | 4.812M |
| December 31, 2024 | 16.04M |
| September 30, 2024 | -143.47M |
| June 30, 2024 | 18.89M |
| March 31, 2024 | 8.979M |
| December 31, 2023 | 24.87M |
| September 30, 2023 | 10.86M |
| June 30, 2023 | 25.76M |
| March 31, 2023 | -19.54M |
| December 31, 2022 | -10.10M |
| September 30, 2022 | -0.693M |
| June 30, 2022 | 19.88M |
| March 31, 2022 | 6.828M |
| December 31, 2021 | -5.129M |
| September 30, 2021 | 17.66M |
| June 30, 2021 | 19.08M |
| March 31, 2021 | 10.37M |
| December 31, 2020 | 14.51M |
| September 30, 2020 | 130.12M |
| Date | Value |
|---|---|
| June 30, 2020 | -7.269M |
| March 31, 2020 | 8.159M |
| December 31, 2019 | -4.888M |
| September 30, 2019 | -6.087M |
| June 30, 2019 | 2.73M |
| March 31, 2019 | -2.771M |
| December 31, 2018 | 8.285M |
| September 30, 2018 | -0.64M |
| June 30, 2018 | 2.564M |
| March 31, 2018 | -10.68M |
| December 31, 2017 | 4.595M |
| September 30, 2017 | -7.597M |
| June 30, 2017 | -19.74M |
| March 31, 2017 | -19.87M |
| December 31, 2016 | -3.973M |
| September 30, 2016 | -22.16M |
| June 30, 2016 | -7.958M |
| March 31, 2016 | -3.854M |
| December 31, 2015 | -2.498M |
| September 30, 2015 | 3.086M |
| June 30, 2015 | 0.008M |
| March 31, 2015 | 1.26M |
| December 31, 2014 | 5.802M |
| September 30, 2014 | -3.004M |
| June 30, 2014 | -5.037M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Viatris, Inc. | -325.30M |
| Organon & Co. | 164.00M |
| ANI Pharmaceuticals, Inc. | 32.72M |
| Corcept Therapeutics, Inc. | 124.49M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 176.65M |
| Total Expenses (Quarterly) | 148.13M |
| EPS Diluted (Quarterly) | 0.6985 |
| Enterprise Value | 1.500B |
| Gross Profit Margin (Quarterly) | 71.93% |
| Profit Margin (Quarterly) | 16.15% |
| Earnings Yield | 2.53% |
| Operating Earnings Yield | 2.06% |
| Normalized Earnings Yield | 2.311 |